Synthesis and absolute configuration of 9-β-D-glucosyloxy-camptothecin, a new gluco camptothecin isolated from *Ophiorrhiza pumila* regenerated plants



Mariko Kitajima, Mio Nakamura, Akihito Watanabe, Hiromitsu Takayama and Norio Aimi*

Faculty of Pharmaceutical Sciences, Chiba University, 1–33, Yayoi-cho, Inage-ku, Chiba 263, Japan

9-β-D-Glucosyloxycamptothecin, which has been obtained from the regenerated plantlets of *Ophiorrhiza pumila*, has been synthesized and its structure and the absolute configuration established.

Introduction

Ophiorrhiza pumila Champ. (Rubiaceae) which grows on the Amami and Ryukyu Islands, Japan, produces a remarkable antitumor alkaloid, camptothecin 1¹ and related alkaloids.^{2a,b}

 $\mathbf{1} R^1 = R^2 = H : Camptothecin$

2 $R^1 = Glc$, $R^2 = H: 9-\beta$ -D-Glucosyloxycamptothecin

3 $R^1 = Glc(OAc)_4$, $R^2 = Ac$

During our chemical investigation of O. pumila,2 we have recently succeeded in regenerating O. pumila from callus cultures. From the regenerated plantlets, a new hydroxycamptothecin glucoside 2 was obtained together with camptothecin 1 and related alkaloids.^{2f} The new metabolite was characterized as the acetate and the structure was elucidated as 9-β-glucosyloxycamptothecin pentaacetate 3 based on spectroscopic studies.^{2f} This compound was the second example of naturally occurring glycosidic camptothecins. We concluded that the position of the glucosyloxy group was at C-9 after an extensive NMR study, and the absolute stereochemistry at C-20 was most probably S as is the case with other natural camptothecins based on a CD spectral comparison (Fig. 1).² The absolute configuration of the sugar, glucose, in 3 was assumed to be D as is encountered in almost all natural glucosides. The validity of the proposed structure including the absolute configuration at the chiral centers was unambiguously proved by the chiral total synthesis, which is described here.

Results and discussion

The Friedländer condensation strategy 3 was adopted for the construction of the entire molecule. For this purpose, the A-ring moiety and CDE-ring counterpart were separately prepared. First, 6-glucosyloxy-2-aminobenzaldehyde 6, corresponding to the A-ring part of 2, was prepared from the known phenol 4^4 as follows. The phenol 4 was condensed with tetra-0-acetyl bromoglucose in the presence of K_2CO_3 in acet-

3 R = Ac 2 R = H: 9- β -D-Glucosyloxycamptothecin




Fig. 1 Comparison of CD spectra for compounds 2 and 3

OR¹
CHO
$$R^{2}$$

4 $R^{1} = H, R^{2} = NO_{2}$
5 $R^{1} = Glc(OAc)_{4}, R^{2} = NO_{2}$
6 $R^{1} = Glc(OAc)_{4}, R^{2} = NH_{2}$

7 $R = H$
8 $R = Ac$

one under reflux to give the 2-glucosyloxy-6-nitrobenzaldehyde 5 in 59% yield. The nitro group in 5 was selectively reduced by hydrogenation (H₂, PtO₂) to afford segment 6. In the ¹H NMR spectrum, the two protons of the amino group were observed as a broad singlet at δ 6.40. The CDE-ring moiety 8 was prepared from known (S)-7 ^{3c} {[a]_D²⁰ +116.4 (c 0.51, CHCl₃)} through

acetylation with AcCl (neat) in 85% yield. In the 1H NMR spectrum, the acetyl methyl protons were observed at δ 2.16. Condensation of the two components 6 and 8 in 5% AcOH–MeOH under reflux gave the camptothecin skeleton 3 in 58% yield. The synthetic compound 3 was identical with the penta-acetate derived from the natural glucoside (TLC, UV, IR, 1H and ^{13}C NMR, CD and mass spectra). 2f Thus the structure of the new compound including the absolute configuration of the sugar moiety and the C-20 position was established. Deacetylation of 3 with K_2CO_3 (10 equiv.) in MeOH at room temperature gave 9- β -D-glucosyloxycamptothecin 2 in 80% yield.

In conclusion, 9-β-D-glucosyloxycamptothecin, the second example of naturally occurring camptothecinoid glucosides, was synthesized in a chiral manner and its absolute configuration was established.

Experimental

Selected data for the A-ring segment $\boldsymbol{6}$

Yellow needles, mp 135 °C (AcOEt) (Found: C, 53.63; H, 5.51; N, 3.06. $C_{21}H_{25}NO_{11}$ requires C, 53.96; H, 5.39; N, 3.00%); δ_H (400 MHz; CDCl₃) 10.26 (1 H, s, CHO), 7.20 (1 H, t, J 8.2†, aromatic-H), 6.40 (2 H, br s, NH₂), 6.33 (1 H, d, J 8.2, aromatic-H), 6.24 (1 H, d, J 8.2, aromatic-H), 5.15 (1 H, d, J 7.3, H-1').

Selected data for the CDE-ring component 8

(Found: C, 58.85; H, 5.25; N, 4.79. $C_{18}H_{15}NO_6$ requires C, 59.01; H, 4.95; N, 4.59%); $\delta_H(500 \text{ MHz}; \text{CDCl}_3)$ 6.76 (1 H, s, aromatic-H), 2.16 (3 H, s, COCH₃), 0.92 (3 H, dd, *J* 7.4 and 7.4, CH₃); CD (c 0.328 mmol dm⁻³, MeOH, 25 °C) $\Delta \epsilon/\text{dm}^3$ mol⁻¹ cm⁻¹ (λ/nm) 0 (377), -0.42 (360), 0 (335), +0.25 (305), +0.14 (287), +2.78 (262), +2.05 (245), +7.90 (233).

Preparation of 9-β-D-glucosyloxycamptothecin tetraacetate 3

AcOH (0.2 cm³) was added to a mixture of the A-ring segment 6 (219 mg, 0.441 mmol) and the CDE-ring component 8 (19 mg, 0.063 mmol) in dry MeOH (4 cm³) and the mixture was refluxed under argon for 11.5 h. The reaction mixture was diluted with CHCl₃, washed with sat. aqueous NaHCO₃ and then with water, dried (MgSO₄) and evaporated. The residue was purified by MPLC (SiO₂, 20% AcOEt-CHCl₃) to afford the camptothecin derivative 3 (26.5 mg, 58%). [HRMS (FAB): found MH⁺, 737.2167. Calc. for C₃₆H₃₇N₂O₁₅, 737.2194]; $\lambda_{\text{max}}(\text{MeOH})/\text{nm}$ 371 (sh), 356, 316, 299, 260; $\nu_{\text{max}}/\text{cm}^{-1}$ 1752, 1235, 1053; δ_{H} (400 MHz; CDCl₃) 8.68 (1 H, s, H-7), 7.94 (1 H, d, J 8.5, H-12), 7.73 (1 H, dd, J 8.5 and 7.9, H-11), 7.21 (1 H, s, H-14), 7.18 (1 H, d, J 7.9, H-10), 5.68 (1 H, d, J 17.3, H-17), 5.40 (1 H, d, J 17.3, H-17), 5.33 (1 H, d, J 19.8, H-5), 5.26 (1 H, d, J 19.8, H-5), 5.34 (1 H, d, J 7.8, H-1'), 2.28 (1 H, dd, J 13.9 and 7.5, H-19), 2.22 (3 H, s, COMe), 2.14 (1 H, dd, J 13.9 and 7.5, H-19), 2.09, 2.08, 2.07 and 2.06 (each 3 H, s, $4 \times COMe$) and 0.98 (3 H, dd, J 7.5 and 7.5, H₃-18); $\delta_{\rm C}$ (125 MHz; CDCl₃) 153.0 (C-2), 146.0 (C-3), 50.2 (C-5), 128.5 (C-6), 126.0 (C-7), 121.1 (C-8), 152.2 (C-9), 110.2 (C-10), 130.2 (C-11), 124.3 (C-12), 149.4 (C-13), 96.2 (C-14), 145.8 (C-15), 120.6 (C-16), 67.1 (C-17), 7.5 (C-18), 31.8 (C-19), 75.9 (C-20), 167.5 (C-21), 157.3 (C-22), 99.1 (C-1'), 71.0 (C-2'), 72.3 (C-3'), 68.2 (C-4'), 72.3 (C-5'), 61.7 (C-6'); CD (c 0.054 mmol dm⁻³, MeOH, 25 °C) $\Delta \varepsilon$ /dm³ mol⁻¹ cm⁻¹ (λ /nm) 0 (396), -1.79 (345), 0 (306), +0.63 (283), 0 (269), -1.04 (263), 0 (253), +4.55 (232), +1.58(217), 0(210).

Preparation of 9-β-D-glucosyloxycamptothecin 2

A mixture of 3 (4.7 mg, 0.006 mmol) and K_2CO_3 (8.7 mg, 0.063 mmol) in dry MeOH (3 cm³) was stirred at rt under argon for 2 h. The reaction mixture was subjected to Amberlite IR-120B eluted with H₂O. The water layer was extracted with Bu"OH and the organic layer was washed with water, then evaporated. The residue was purified by SiO₂ column chromatography (25% MeOH-CHCl₃) to give 2 (2.7 mg, 80%). m/z (FAB, NBA) 527 (MH⁺) [HRMS (FAB): found MH⁺, 527.1660. Calc. for $C_{26}H_{27}N_2O_{10}$, 527.1666]; $\lambda_{max}(MeOH)/nm$ 372 (sh), 359, 319, 304, 262; $\delta_{H}(400 \text{ MHz}; [^2H_6]DMSO)$ 9.01 (1 H, s, H-7), 7.81 (1 H, d, J7.9, H-12), 7.77 (1 H, dd, J7.9 and 7.9, H-11), 7.36 (1 H, d, J7.9, H-10), 7.34 (1 H, s, H-14), 6.53 (1 H, s, 20-OH), 5.42 (2 H, s, H-17), 5.34 (1 H, d, J 19.8, H-5), 5.26 (1 H, d, J 19.8, H-5), 5.11 (1 H, d, J 7.8, H-1'), 4.62 (1 H, dd, J 6.1 and 5.9, 6'-OH), $3.73(1 \text{ H}, \text{m}, \text{H-6'}), 3.44(1 \text{ H}, \text{m}, \text{H-6'}), 3.44(3 \text{ H}, \text{m}, \text{H-3'}-5'\ddagger),$ 3.27 (1 H, m, H-2'\dagger), 1.86 (2 H, m, H-19) and 0.87 (3 H, m, H-18); $\delta_{\rm C}$ (125 MHz; [2 H₆]DMSO) 152.8 (C-2), 145.5 (C-3), 50.4 (C-5), 129.2 (C-6), 126.5 (C-7), 120.4 (C-8), 153.0 (C-9), 96.8 (C-10), 130.5 (C-11), 122.4 (C-12), 148.6 (C-13), 110.2 (C-14), 150.0 (C-15), 119.1 (C-16), 65.3 (C-17), 7.8 (C-18), 30.3 (C-19), 72.4 (C-20), 172.5 (C-21), 156.9 (C-22), 101.1 (C-1'), 69.7 $(C-2')^{\ddagger}$, 73.4 $(C-3')^{\ddagger}$, 76.4 $(C-4')^{\ddagger}$, 77.3 $(C-5')^{\ddagger}$ and 60.7 (C-6'); CD (c 0.247 mmol dm⁻³, MeOH, 25 °C); Δε/dm³ mol⁻¹ cm^{-1} (λ /nm) 0 (389), -0.42 (354), 0 (318), +0.31 (276), +0.26(266), +3.44(234), 0(216).

Acknowledgements

Our thanks are due to the Ministry of Education, Science, Sports and Culture, Japan, for a Grant-in-Aid for Scientific Research (No. 08457578).

‡ Interchangeable.

References

- 1 (a) C. R. Hutchinson, *Tetrahedron*, 1981, 37, 1047; (b) J.-C. Cai and C. R. Hutchinson, in *The Alkaloids*, ed. A. Brossi, Academic Press, New York, 1983, vol. 21, p. 101; (c) M. E. Wall and M. C. Wani, in *The Monoterpenoid Indole Alkaloids*, ed. J. E. Saxton, Wiley, London, 1994, ch. 13, p. 689.
- 2 (a) N. Aimi, M. Nishimura, A. Miwa, H. Hoshino, S. Sakai and J. Haginiwa, *Tetrahedron Lett.*, 1989, **30**, 4991; (b) N. Aimi, H. Hoshino, M. Nishimura, S. Sakai and J. Haginiwa, *Tetrahedron Lett.*, 1990, **31**, 5169; (c) N. Aimi, M. Ueno, H. Hoshino and S. Sakai, *Tetrahedron Lett.*, 1992, **33**, 5403; (d) M. Kitajima, S. Masumoto, H. Takayama and N. Aimi, *Tetrahedron Lett.*, 1997, **38**, 4255; (e) M. Kitajima, U. Fischer, M. Nakamura, M. Ohsawa, M. Ueno, H. Takayama, M. Unger, J. Stöckigt and N. Aimi, *Phytochemistry*, in press. (f) M. Kitajima, M. Nakamura, H. Takayama, K. Saito, J. Stöckigt and N. Aimi, *Tetrahedron Lett.*, 1997, **38**, 8997.
- 3 Shanghai No. 5 and No. 12 Pharmaceutical Plant, Shanghai Institute of Pharmaceutical Industrial Research and Shanghai Institute of Materia Medica, *Sci. Sin. Ser. B*, 1978, **21**, 87; (*b*) M. C. Wani, P. E. Ronman, J. T. Lindley and M. E. Wall, *J. Med. Chem.*, 1980, **23**, 554; (*c*) A. Ejima, H. Terasawa, M. Sugimori and H. Tagawa, *J. Chem. Soc.*, *Perkin Trans. 1*, 1990, 27.
- 4 J. N. Ashley, W. H. Perkin and R. Robinson, *J. Chem. Soc.*, 1930, 382.
 5 T. Yaegashi, S. Sawada, S. Okajima and T. Miyasaka, Jpn. Kokai Tokkyo Koho JapP 63 238 098.

Paper 7/08263K Received 17th November 1997 Accepted 10th December 1997

 $[\]dagger$ J Values are given in Hz.